Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  
 
 

Your Health

Contact Us

sanofi-aventis Pakistan limited

Registered Office

Plot 23, Sector 22
Korangi Industrial Area
Karachi-74900

Postal Address

P.O. Box 4962
Karachi-74000

Tel: +92-21-35060221-35

Content :

Central Nervous System

Central Nervous system

Our research and development division is committed to discovering new products that will make a difference in people's lives.

 

A cluster of complex diseases

Because of the complexity of the human neuronal system, most of the diseases affecting the central nervous system (CNS) do not receive optimal treatment with currently available therapies.

Central Nervous System

CNS Disorders

Some of these conditions are:

  • Alzheimer’s disease: a neurodegenerative pathology, which progressively impairs cognitive ability, and brings about behavioral disorders and functional deterioration leading to dementia,
  • Multiple Sclerosis (MS): characterized by destruction of the myelin, which covers and protects the nerves of the central nervous system,
  • Schizophrenia: generally a chronic disease marked by delirium, hallucinations or introspection and
    Inability to act,
  • and also insomnia, anxiety, Parkinson’s disease...

These are major public health issues

Approximately 22 million patients suffer from various forms of dementia, two thirds of which are related to Alzheimer’s. Prevalence of this disease could double within the next 25 years. The WHO (World Health Organization) estimates the number of people suffering from multiple sclerosis worldwide at 2.5 million. As for schizophrenia, 1% of the world’s population may be at risk.

Targeted disorders

  • Sleep disorders
  • Schizophrenia and bipolar disorders
  • Nicotine withdrawal
  • Neurogenic pain
  • Depression Alzheimer’s disease
  • Anxiety Parkinson’s disease
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis

As well as the reference therapy for treating epilepsy, Sanofi-Synthelabo medicines for central nervous system disorders range from hypnotics for treating insomnia to new compounds for stabilising the extreme mood swings associated with bipolar disorder and a novel anti-psychotic for controlling the symptoms of schizophrenia.

Updated September 02, 2014

Module :